Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Betaxolol
Drug ID BADD_D00263
Description A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Indications and Usage For the management of hypertension.
Marketing Status approved; investigational
ATC Code C07AB05; S01ED02
DrugBank ID DB00195
KEGG ID D07526
MeSH ID D015784
PubChem ID 2369
TTD Drug ID D03ROX
NDC Product Code 42806-039; 24658-700; 42806-038; 24658-701
UNII O0ZR1R6RZ2
Synonyms Betaxolol | Betaxolol Hydrochloride | Hydrochloride, Betaxolol | Kerlone | Oxodal | Kerlon | SL-75212 | SL 75212 | SL75212 | ALO-1401-02 | ALO 1401 02 | ALO140102 | Betoptic | Betoptima | Betaxolol Alcon | Alcon, Betaxolol
Chemical Information
Molecular Formula C18H29NO3
CAS Registry Number 63659-18-7
SMILES CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual acuity reduced06.02.10.012; 17.17.01.011--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Emotional distress19.04.02.008--Not Available
Musculoskeletal chest pain15.03.04.012; 22.09.01.001--
Foreign body sensation in eyes06.01.01.006--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.005--Not Available
Eye pruritus06.04.05.006--Not Available
Ocular discomfort06.08.03.008--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene